Lantern Pharma's HARMONIC trial for LP-300 demonstrated an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with enrollment expanding in Japan and Taiwan where never-smokers represent up to 40% of NSCLC cases.
The FDA granted Fast Track Designation to Lantern Pharma's LP-184 for treating Triple Negative Breast Cancer (TNBC), marking its second Fast Track Designation in 2024.